Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-00489791 + diltiazem
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PF-00489791 + diltiazem** is an investigational combination of two small molecule pharmaceuticals: PF-00489791, a potent phosphodiesterase 5A (PDE5A) inhibitor developed by Pfizer, and diltiazem, a widely used calcium channel blocker. PF-00489791 exerts its effects by enhancing cyclic GMP-mediated vasodilation and has been studied for its blood pressure-lowering effects and for kidney protection in the context of type 2 diabetes and nephropathy[3][6][7]. Diltiazem inhibits the influx of calcium ions into cardiac and smooth muscle cells, leading to vasodilation and reduced myocardial oxygen demand[2]. The combination aims to provide complementary mechanisms for cardiovascular conditions, especially hypertension and angina, though no approved product contains both as a fixed-dose combination.
- Other names
- PF-0489791PF0489791PF 0489791PF 489791PF489791PF-489791diltiazem
02
Targets
PDE5A (Cyclic GMP-specific phosphodiesterase 5A)
Beyond the preview
Go deeper on PF-00489791 + diltiazem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-00489791 + diltiazem.